Pharmacokinetic considerations in the treatment of tuberculosis in patients with renal failure

Clin Pharmacokinet. 2005;44(3):221-35. doi: 10.2165/00003088-200544030-00001.


Tuberculosis is re-emerging in patients with altered immune status, such as those with chronic renal failure. Clinicians should thus be aware of the pharmacokinetics and dosage adjustment of antitubercular drugs in patients with renal insufficiency. Among patients with renal insufficiency, those who are dialysed should be treated with special care. Indeed, dosage should always be closely adjusted in these patients and potential removal by dialysis must be taken into account. However reliable the dosage adjustment recommendations are for these drugs in patients with renal failure, further pharmacokinetic investigations need to be performed, especially in dialysis patients in whom the influence of haemodialysis and continuous ambulatory peritoneal dialysis on drug pharmacokinetics needs to be detailed. In the meantime, it could be generally advised to administer all antitubercular drugs after the haemodialysis session, even though some drugs are known to be non-dialysable.

Publication types

  • Review

MeSH terms

  • Antitubercular Agents / administration & dosage
  • Antitubercular Agents / pharmacokinetics*
  • Antitubercular Agents / therapeutic use*
  • Drug Monitoring
  • Humans
  • Renal Insufficiency / complications
  • Renal Insufficiency / metabolism*
  • Tuberculosis / complications
  • Tuberculosis / drug therapy*
  • Tuberculosis / metabolism


  • Antitubercular Agents